Personas / Equipo Humano

Manuel Vázquez Carrera

Buscador de publicaciones

Publicaciones

  • Palomer FX, Pizarro J and Vazquez M.

    Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets?

    TRENDS IN PHARMACOLOGICAL SCIENCES . 39(5): 452-467. Nº de citas: 65

    [doi:10.1016/j.tips.2018.02.010]

  • Palomer FX, Barroso E, Pizarro J, Peña L, Botteri G, Zarei M, Aguilar D, Montori M and Vazquez M.

    PPARß/d: A Key Therapeutic Target in Metabolic Disorders.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 19(3): . Nº de citas: 73

    [doi:10.3390/ijms19030913]

  • Palomer FX, Pizarro J, Barroso E and Vazquez M.

    Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus.

    TRENDS IN ENDOCRINOLOGY AND METABOLISM . 29(3): 178-190. Nº de citas: 359

    [doi:10.1016/j.tem.2017.11.009]

  • Zarei M, Barroso E, Palomer FX, Dai J, Rada P, Quesada T, Escolà-Gil JC, Cedó L, Zali MR, Molaei M, Dabiri R, Vázquez S, Pujol E, Valverde ÁM, Villarroya-Gombau F, Liu Y, Wahli W and Vazquez M.

    Hepatic regulation of VLDL receptor by PPARß/d and FGF21 modulates non-alcoholic fatty liver disease.

    molecular metabolism . 8: 117-131. Nº de citas: 79

    [doi:10.1016/j.molmet.2017.12.008]

  • Botteri G, Montori M, Gumà A, Pizarro J, Cedó L, Escolà-Gil JC, Li D, Barroso E, Palomer FX, Kohan AB and Vazquez M.

    VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells.

    Diabetologia . 60(11): 2262-2273. Nº de citas: 29

    [doi:10.1007/s00125-017-4401-5]

  • Rodríguez-Calvo R, Chanda D, Oligschlaeger Y, Miglianico M, Coumans WA, Barroso E, Tajes M, Luiken JJ, Glatz JF, Vazquez M and Neumann D.

    Small heterodimer partner (SHP) contributes to insulin resistance in cardiomyocytes.

    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE . 1862(5): 541-551. Nº de citas: 9

    [doi:10.1016/j.bbalip.2017.02.006]

  • Rodríguez-Calvo R, Tajes M and Vazquez M.

    The NR4A subfamily of nuclear receptors: potential new therapeutic targets for the treatment of inflammatory diseases.

    EXPERT OPIN THER TAR . 21(3): 291-304. Nº de citas: 92

    [doi:10.1080/14728222.2017.1279146]

  • Palomer FX, Barroso E, Zarei M, Botteri G and Vazquez M.

    PPAR beta/delta and lipid metabolism in the heart

    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS . 1861(10): 1569-1578. Nº de citas: 38

    [doi:10.1016/j.bbalip.2016.01.019]

  • Tan NS, Vazquez M, Montagner A, Sng MK, Guillou H and Wahli W.

    Transcriptional control of physiological and pathological processes by the nuclear receptor PPARß/d.

    PROG LIPID RES . 64: 98-122. Nº de citas: 57

    [doi:10.1016/j.plipres.2016.09.001]

  • Vazquez M.

    Unraveling the Effects of PPAR beta/delta on Insulin Resistance and Cardiovascular Disease

    TRENDS IN ENDOCRINOLOGY AND METABOLISM . 27(5): 319-334. Nº de citas: 53

    [doi:10.1016/j.tem.2016.02.008]